Anavex Life Sciences reported a narrower net loss in Q1 FY2026 as research and development and general and administrative expenses declined materially, while the company maintained a strong cash position supporting a multi-year runway.

Anavex Life Sciences Corp. reported a net loss of $9.8 million for the fourth quarter of fiscal 2025, or $0.11 per share, compared to a net loss of $11.6 million, or $0.14 per share, for the comparable fourth quarter of fiscal 2024. The company's cash and cash equivalents decreased to $102.6 million at September 30, 2025, from $132.2 million at September 30, 2024, but it anticipates a cash runway of more than 3 years with its current cash balance of over $120 million. Research and development expenses were $7.3 million, down from $11.6 million in the prior year.

In Q3 2025, Anavex Life Sciences posted a net loss of $13.2 million, reflecting increased general and administrative spending while research and development costs declined. The company maintains a strong cash position with over $101 million in reserves and expects its current cash to support operations for more than three years.

Anavex Life Sciences reported a net loss of $11.2 million for the second quarter of fiscal 2025, compared to a net loss of $10.5 million in the same period last year. The company's cash and cash equivalents stood at $115.8 million as of March 31, 2025.

Anavex Life Sciences reported its financial results for the fiscal quarter ended March 31, 2024, and provided a business update. The company is encouraged by the FDA guidance for Early Alzheimer’s disease and the progress of the Marketing Authorisation application to the European Medicines Agency (EMA) for blarcamesine related to the treatment of Alzheimer’s disease.

Anavex Life Sciences reported its financial results for the fiscal year ended September 30, 2020, highlighting significant progress across its portfolio, including positive trial results for ANAVEX®2-73 in Rett syndrome and Parkinson's disease dementia.